NEWSLETTER 10
-
Upload
saudi-gastro-association -
Category
Documents
-
view
212 -
download
0
description
Transcript of NEWSLETTER 10
Issue No.: NL 10 /2013 Date: July 2013 Newsletter Editor: Dr. Nahla Azzam
In this issue: 1. SGA LATEST SCIENTIFIC PARTICIPATIONS:
A. IBD Awareness Campaign 2013(Yes I Can)
B. IBD Clinical Observation Program 2013
C. “Update in Gastroenterology & Liver Diseases”
D. 6th Endoscopy Guide workshop
2. HOT TOPICS IN HEPATOLOGY & GASTROENTEROLOGY..
3. UPCOMING SCIENTIFIC EVENTS
IBD AWARENESS CAMPAIGN
4. GUT CLUB SCHEDULE FOR 2013
SGA Monthly GUT Club Meeting in Riyadh.
For More Information, please contact SGA
Office at:
TEL/FAX: 01-4679130
EMAIL: [email protected]
SGA Website: www.saudigastro.com
SGA journal: www.saudijgastro.com
Our Vision:
SGA aims to be a leading organization in the field of
gastroenterology with a significant positive impact on
patient care in the Middle East .
Our Mission:
To advance the science and practice of Gastroenterology
and Endoscopy in Saudi Arabia.
Current SGA Board of directors:
Dr. Abdulrahman AlJebreen, SGA President
Dr. Abdulllah Al-Ghamdi SGA Vice President
Dr. Ayman A. Abdo, SGA Treasure
Dr. Fahad AL Sohaibani SGA Board Secretary
Dr Faisal Sanai, SGA Board Member
Dr. Faisal Batwa, SGA Board Member
Dr. Mohamed AL Shumrany, SGA Board Member
Dr. Nahla Azzam, SGA Board Member
Dr. Hanan AL Ghamdi, SGA Board Member
1. SGA Latest Scientific Participations:
A. IBD Awareness Campaign 2013(Yes I Can)
11th of April 2013, succeeding Awareness campaign
was held at Al Khozama Hotel and Towers. More or
less than 100 Attendees are our patients from different
hospitals in Riyadh. Lectures took place, some of the
topics discussed were the Disease nature and its
etiology , When is the right time to seek consultation
once symptoms exists, the New Trends in IBD
Treatment, Comparison in the old and new IBD
medications , the relationship of lifestyle with the
disease, and the different surgical options for IBD
patients.
As part of the Program, patients were given an
opportunity to express their doubts, questions and
clarifications related to IBD and our Respected
Speakers: Dr. Othman Al Harbi Dr. Nahla Azzam, Dr.
Abdullah Mtawa, Dr. Ahmed Almalki and Dr. Khyal
Alkhyal generously answered them.
Booths were also made available with Health
Educators and Dieticians to further educate them.
Arabic and English Brochures, T-Shirts, Mugs and
other Souvenirs were distributed. Medical Students
were also present from the beginning until the end of
the Program to help and assist us.
Dinner was served after all the activities.
There’s no time to Stall! 11th of June 2013, “IBD
Awareness Campaign - YES I CAN” in a Mall Clinic
Set up was a success as per attendees’ feedback.
At the Gate 3, Open Grounds of Sahara Mall,
Gastroenterologist’s Booth, Health Educator’s Booth,
Dietician’s Booth and Kid’s Activity Booth was
crowded most of the time.
Please refer to the UPCOMING ACTIVITIES’
SECTION for the next “IBD Awareness Campaign”
Schedule.
KKUH Gastroenterology Unit and Saudi
Gastroenterology Association would like to
acknowledge ABBOTT PHARMACEUTICALS,
Riyadh for their sponsorship and made this Workshop
a Success!
Inflammatory Bowel Disease (IBD) is a chronic disease
of unknown etiology and considered traditionally as a
disease of the Western World. Ulcerative colitis (UC)
and Crohn's disease (CD) are chronic inflammatory
disorders of the gastrointestinal tract that have a
significant lifelong impact on a patient's quality of life
with a highly variable and uncertain clinical course. The
prevalence rate of these inflammatory bowel diseases
(IBDs) reach up to 396/100,000 people worldwide, with
a remarkable and sharply increase in the disease
incidence among Saudi population.
King Khalid University Hospital- Gastroenterology
Division and Saudi Gastroenterology Association never
relinquish to the increasing number of IBD Cases in
Saudi Arabia through continuous studies and research.
In addition to that, activities such as “IBD Awareness
Campaign” precedes to promote health and raise public
awareness of the Disease and its nature.
On the 8th
of April 2013, Opening Ceremony for this
year’s IBD Awareness Campaign entitled “YES I
CAN” was held. The Cutting of Ribbon was lead by Dr.
Othman Al Harbi and Dr. Nahla Azzam with the
presence of our Honorable Dean Prof.Professor
Mubarak Alfaran Physicians, Health Educators,
Dieticians, Medical Students, Company Representatives
and other Supporting Staffs were present and have their
own booth to ensure that the guest needs will be
accommodated. Information dissemination thru health
education to patients and their families is our focal
point. For the children’s booth, Interactive Kids
Activities took place.
B. IBD Clinical Observation Program 2013 C. “Update in Gastroenterology & Liver Diseases”
Under the auspices of Saudi Association for
Gastroenterology and in collaboration with King
Fahad Hospital and the Internal Medicine Department
in Albaha, an Evening symposium held in Al Baha
Tulip Hotel on Wednesday 7th Jumada Thani 1434
corresponding to 17th April 2013 with the title:
“Update in Gastroenterology & Liver Diseases”
This symposium was accredited by Saudi
Commission for Health Specialties with 10 CME
hours. The programme of the conference is created to
provide the participants with the latest recommended
guidelines on, clinical pictures and managements of
common gastrointestinal as well as hapatology
disorders. More than 120 participants from Al Baha
regions attended the conference.
On this occasion and on behalf of Albaha region
people Dr Mohamad Alshumrany, SGA Board
member extended his sincere thanks and appreciation
to Saudi Association for Gastroenterology, led by his
Excellency Dr.Abdul Rahman Al-Jebreen the SGA
President and The SGA Board members for their
industrious hard work and contributions in to increase
Health Education for physicians over all the Kingdom
of Saudi Arabia and provide of the Health Education
Bulletin & Brochures to patients and their families by
the SGAand their contribution in the success of the
very distinguished event.
With the continuous efforts of King Khalid University
Hospital Gastroenterology Unit Team and IBD Chairs
in Collaboration with Saudi Gastroenterology
Association, another successful Activity was conducted
last 3rd
– 4th
of April, 2013. The Program entitled “IBD
Clinical Observation Program” was launched to yield
our Fellows and Junior Gastroenterologist with
multidisciplinary broad base of knowledge in
Inflammatory Bowel Disease that ultimately aims to
improve the quality of care for patients with IBD in
Saudi Arabia.
The programme of the workshop is created to provide
the participants with the latest ECCO guidelines on
Crohn's Disease and Ulcerative Colitis definition,
clinical pictures and managements that were delivered
through lectures, clinical cases illustration by a set of
ECCO Statements. Difficult cases were discussed by the
expert Gastroenterologist. Active discussions and
exchange of ideas among the participants and speakers
were ordained throughout these 2-days. A gala dinner at
Holiday Iz-Dihar was held on the first day.
The highlights of the Program is a Tour Visit in
KKUH’s Day Care Unit where Biological Treatment is
given to IBD Patients.
Among the prestigious Speakers were Dr. Abdulrahman
Al Jebreen (SGA President-KKUH), Dr. Othman Al
Harbi (Head G.E. Unit-KKUH), Dr. Majid Al Madi
(Director, Endoscopy Unit-KKUH), Dr. Nahla Azzam
(SGA Board Member- KKUH), Dr. Khayal Al Khayal
(Colorectal Surgeon-KKUH) and Dr. Reem Al Amro
(Consultant-Riyadh Military Hospital).
15 of the attendees were Consultants, Senior Registrars,
Registrars, Residents and Junior Gastroenterologists
from different regions of Riyadh such as Hail, Al Hasa,
Al Manura, Madinah, Arar, Hofuf, Yanbu, Taif,
Buraidah Qassim and Riyadh as well.
Certificate of Participation plus a 15-SCFHS CME
Credit Hours was awarded to all the Attendees and
participants.
Succeeding ICOP will be announced soon. For any
inquiries and suggestions, please don’t hesitate to send
an email to [email protected].
This Activity is Sponsored by JANSSEN
PHARMACEUTICALS, Riyadh, KSA.
D. 6th
Endoscopy Guide workshop
It is with great pleasure for KKUH-
Gastroenterology Division in Collaboration with
the Saudi Gastroenterology Association to hold a
“Quarterly-based Endoscopy Guide
Workshop” that has always been part of our
Routine Activity for almost 2 years.
Closing Ceremony was conducted last April 30,
2013 at King Khalid University Hospital lead by
Dr. Othman Al Harbi, on behalf of all the
benefactors of the Workshop and Internal
Speakers: Dr. Khalid Al Swat, Dr. Abdulrahman
Al Jebreen, Dr. Nahla Azzam, Dr. Ayman Abdo
,and Dr. Majid Al Madi,Supporting Staffs from
Clinical Skills Simulation Department, Saudi
Gastroenterology Association Staff, Sponsoring
Company Representatives and Workshop
Organizers were present to receive the Plaque of
Appreciation and Certificates for their continued
support for the activity. Prestigious Speakers from
different Health Institutions of Saudi Arabia were
also invited such as Dr. Abed Lehibi,Dr. Khalid
Sayari and Dr. Abdullah Mtawa (King Fahed
Medical City ) to give recognition for their never-
ending Support.
We truly appreciate the exceptional efforts of our
distinguished speakers that from the very first day
of the workshop until its last day shared their
knowledge and skills thru Lectures and Interactive
Clinical Hands-on Training using the Olympus
Scope Guide.
To all the energetic and passionate Junior
Gastroenterologists and Colleagues who
participated, Thank you for attending the activity,
we hope that you found the workshop informative
and worthwhile.
Our primary goal was achieved. Many topics
covered during the workshop and the presenters
did an outstanding job of sharing their expertise.
After receiving positive feedback, the Unit may
possibly conduct the same activity in the future and
we will keep you posted.
KKUH Gastroenterology Unit and Saudi
Gastroenterology Association would like to
acknowledge SALEHIYA OLYMPUS, Riyadh for
their sponsorship and made this Workshop a
Success!
Faldaprevir is a potent selective inhibitor of
hepatitis C virus NS3/4A protease, and has antiviral activity against hepatitis C genotypes 1,
2, 4, 5, and 6 in vitro. It can be administered orally
once a day.
STARTVerso 1 a phase III placebo-controlled
trial,conducted in Europe and Japan for chronic
hepatitis c naive patients with genotype 1 .The
study was presented at the International Liver CongressTM (ILC), The 48th Annual Meeting of
the European Association for the Study of the
Liver (EASL), 24-28 April, 2013
Investigators randomized participants to 1 of 3
groups in a 1:2:2 ratio One group took placebo
plus interferon alfa-2a 180 μg/week plus weight-based ribavirin for 24 weeks, with an additional 24
weeks of interferon and ribavirin (control group; n
= 132). Another group took faldaprevir 120 mg
daily for 12 or 24 weeks (guided by response) plus interferon and ribavirin (low-dose group; n = 259).
The third group took faldaprevir 240 mg daily for
12 weeks with interferon and ribavirin for the entire 24 weeks (high-dose group; n = 261).
Patients in the 2 faldaprevir groups had
significantly better virologic responses 12 weeks
after the end of therapy than those in the control group (80 % vs52 ) with similar response rates for
both doses of faldsprevir (120 and 240 mg)
With regards the safety, more than 90% of patients in each group experienced an adverse event, but
only 4% to 5% in each group discontinued all
medication. Serious adverse events affected only 6% to 7%. Anemia was the most frequent adverse
event, and was related to ribavirin. Rash was also
common, affecting 6% to 9% of patients.
Treatment with sofosbuvir results in a rapid and sustained virologic response in patients with
hepatitis C virus (HCV), it is nucleotide analogue
that inhibits HCV replication which showing promise when given together with ribavirin or in
addition to pegylated interferon (peginterferon)
alfa-2a for a variety of genotypes1,2 and 3 and in
different patient populations in phase 2 trial, several studies involving sofosbuvir resulted in a
significant paradigm shift in the management of
hepatitis C.
Those studies were presented at the International
Liver CongressTM (ILC), The 48th Annual
Meeting of the European Association for the Study of the Liver (EASL), 24-28 April, 2013and
the findings are published online April 23 in the
New England Journal of Medicine .
In the NEUTRINO open-label study, 327 patients infected with HCV genotypes 1(more than 90%),
4, 5, or 6 received sofosbuvir, ribavirin, and
peginterferon alfa-2a for 12 weeks. Sofosbuvir was given orally at a dose of 400 mg, once a day,
along with ribavirin, also given orally in a dose
based on weight. Patients who weighed less than
75 kg received 1000 mg/d, and heavier patients received 1200 mg/d. Patients received
peginterferon alfa-2a subcutaneously once a week
at a dose of 180 μg. In this single-group study, investigators report a sustained virologic response
in 90% of patients
In the noninferiority study known as the FISSION trial, patients with hepatitis C genotype 2 or 3
were randomly assigned to 12 weeks of treatment
with sofosbuvir plus ribavirin or to 24 weeks of
treatment with peginterferon alfa-2a plus ribavirin. For the peginterferon-ribavirin group,
the ribavirin dose was 800 mg/d given in 2
divided doses.The sofosbuvir-based regimen was successful in 97% of patients with genotype 2
infection and 56% successful in those with
genotype 3 infection compared with 78% and 63% in the standard peginterferon alfa-2a plus ribavirin
group.
Investigators report that discontinuation rates due
to adverse effects were low (2%) among patients receiving sofosbuvir-containing regimens.
2. HOT TOPICS IN HEPATOLOGY & GASTROENTEROLOGY
1. News from EASL April 2013
A. Faldaprevir achieved viral cure in 80%
of treatment-naïve hepatitis C patients
B. Sofosbuvir for Previously Untreated
Chronic Hepatitis C Infection
Stem Cell Transplantation is a promising solution
for moderate-severe Crohn's Disease ,based on
study presented in DDW 2013 This is not the first
study to evaluate bone marrow transplantation in
Crohn's disease however, it is the first randomized
trial looking at the effect of stem cell transplantation
for moderate to severe crohn's disease on at least 3
immunosuppressive drugs. At 1 year the patients in
the treatment arm (stem cell therapy) were able to
stop the immunosuppressive therapy and around
50% had clinical response with decrease in Crohn's
Disease Activity Index score (CDAI) in the
treatment group than in the control group
(approximately 165 vs 50 points) but more studies
needed to look at the long term risk/benefit.
Inflammatory bowel disease (IBD) affects a
substantial number of female patients in their
reproductive years. Therefore, many physicians face
the dilemma whether thiopurines, prescribed to
maintain remission, can be taken safely during
pregnancy. Data on long-term development
outcome of children exposed to maternal thiopurine
therapy are very limited.
The aim of the study was to assess the long-term
effects of in utero exposure to thiopurines during
pregnancy on infant health status.
It is a prospective multicentre follow-up study was
performed in children exposed intrauterine to
maternal thiopurine therapy. Physical, cognitive
and social aspects of infant health status were
assessed with the 43-item TNO-AZL Preschool
Children Quality of Life Questionnaire (TAPQOL).
Furthermore, information on visits to general
practitioner and medical specialists, and physician's
advice regarding lactation was evaluated. Data
were compared with normative data from a control
group consisting of 340 children.
Thirty children were included in this study [median
3.8 years (IQR 2.9–4.7)]. No differences on global
medical and psychosocial health status were found
between children exposed to intrauterine
thiopurines and the reference group. Exposure to
intrauterine thiopurines was not associated with
increased susceptibility to infection or
immunodeficiency in childhood. Twenty-one of 30
children were exclusively formula-fed based on a
negative advice of medical specialists directed at
thiopurine use during lactation.
The authors concluded that thiopurine use during
pregnancy did not affect long-term development or
immune function of children up to 6 years of age.
Alimentary Pharmacology & Therapeutics, July
2013, Issue 1(38), pages 38–43.
2.NEWS from DDW May 2013
A. Stem Cell Transplantation for
treatment of moderate-severe Crohn's
Disease
3. Long-term follow-up of children exposed
intrauterine to maternal thiopurine therapy
during pregnancy in females with inflammatory
bowel disease
HOSPITAL TIME DATE DAY
RKH
8:30 pm
26/10/1434 (02.09.2013)
Monday
KFSH&RC
8:30 pm
24/11/1434 (30.09.2013)
Monday
KSMC
8:30 pm
23/12/1434 (28.10.2013)
Monday
DAY DATE LOCATION
TIME
Wednesday-
Thursday 25-26/9/2013 Sahara Mall 6pm-9pm.
Wednesday-
Thursday 13-14/11/2013 Gurnadah Mall 6pm-9pm.
Wednesday-
Thursday 25-26/12/2013 Salam Mall 6pm-9pm.
4. GUT CLUB Schedule for 2013
SGA MONTHLY GUT CLUB
MEETING IN RIYADH.
VENUE: KFHU TIME: 8:00 – 10:00 PM
This is a public activities in Arabic which
will be conducted throughout the whole year
Our target is IBD patients as well as the
public to get to know more about the
disease.
IBD AWARENESS CAMPAIGN
(YES, I CAN…….)
3. Upcoming Scientific Events
Thank You,
Greetings from SGA
Team